ACTU SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Actuate Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice

Oct 30, 2026

8-K

Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering

Oct 28, 2026

8-K

Actuate Therapeutics Receives Nasdaq Deficiency Notice Regarding Market Value Requirement

Jul 17, 2026

8-K

Actuate Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 22, 2026

8-K

Actuate Therapeutics Receives FDA Clearance for Oral Elraglusib IND and Announces Strategic Development Initiatives

May 11, 2026

8-K

Actuate Therapeutics Appoints Dr. Martin Huber to Board of Directors

May 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Oct 28, 2026

424B5

November 2025 ATM | Offering amount: $100,000,000

Nov 28, 2025

424B5

REGISTERED OFFERING

Sep 10, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Lucid Capital Markets, LLC

Sep 9, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 1,332,994 | Warrants amount: 666,497 |

Aug 4, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 3,904,374 | Offering amount: $50,000,000

Apr 16, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-1/A

OFFERING | Bank: Newbridge Securities Corporation EFFECTIVE, DATED 2026-10-26

Oct 19, 2026

S-1/A

OFFERING EFFECTIVE, DATED 2026-10-26

Oct 14, 2026

FWP

OFFERING

Oct 8, 2026

S-1

OFFERING (Firm Commitment) - Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC EFFECTIVE, DATED 2026-10-26

Oct 6, 2026

DRS

Form DRS - Draft Registration Statement

Jun 8, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 14, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 6, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 6, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 6, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 8, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 8, 2025

Ownerships

TYPE

HEADLINE

FILED AT

DEMETRIADES JAMES T (Reporting)

Nov 2, 2026

BIOS Fund III NT, LP (Reporting)

Oct 30, 2026

SCHEDULE 13G

Hexstone Capital LLC (Filed by)

Oct 30, 2026

BIOS Fund I, LP (Reporting)

Oct 30, 2026

SCHMITT DANIEL M (Reporting)

Oct 29, 2026

SCHMITT DANIEL M (Reporting)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 27, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 9, 2025

CORRESP

Form CORRESP - Correspondence

Sep 4, 2025

CORRESP

Form CORRESP - Correspondence

Sep 2, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 26, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 5, 2025

Actuate Therapeutics Inc ACTU · SEC Filings